NEW YORK (GenomeWeb) – Exact Sciences reported before the opening of the market on Tuesday that its second quarter revenues more than doubled year over year thanks in large part to a 160 percent increase in the number of Cologuard colorectal cancer screening tests completed during the quarter.

For the three months ended June 30, the molecular diagnostics firm reported revenues of $21.2 million, up from $8.1 million a year ago, and beating the consensus Wall Street estimate of $18.5 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.